Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study

Everdingen, M.H.J. van den Beuken-van; Peters, Madelon L.; Rijke, Janneke M. de; Schouten, Harry C.; Kleef, Maarten van; Patijn, Jacob

doi:10.1002/pon.1340

Cited by 153 publications

(150 citation statements)

References 55 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…HADS has been found to perform well in assessing the symptom severity and classification of anxiety disorders and depression, 26 and its sensitivity and specificity are comparable with other selfreported measures such as Beck Depression Inventory, 27,28 General Health Questionnaire, 26 and observer-rated scales such as Hamilton Rating Scale for Depression. 28 HADS has been used to identify anxiety and depression in patients in clinical studies of many diseases, including cancer, 29 Parkinson disease, 30 and multiple sclerosis. 31 Recently, Lambert et al 32 reported results from a study of 711 patients with moderate-to-severe psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Langley

Feldman

Han

et al. 2010

Journal of the American Academy of Dermatology

182

180

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Langley

Feldman

Han

et al. 2010

Journal of the American Academy of Dermatology

182

180

View full text Add to dashboard Cite

“…Everdingen et al in a study conducted on 136 patients with breast cancer showed that one of the dilemmas of patients after hearing about their cancer is concerns about their life and death (12).…”

Section: Discussionmentioning

confidence: 99%

Investigating the Mental Experience of Patients Suffering From Cancer

Abdollahzadeh

Moodi

Khanjani

2017

Jundishapur J Chronic Dis Care

View full text Add to dashboard Cite

Background: Despite the remarkable development of medical sciences, cancer has yet remained one of the most important diseases of the current century and the second cause of death following cardiovascular diseases. Although we witnessed considerable development in treating cancer and increased number of survivors, cancer is a unique disease that makes the patients deeply feel helplessness and fear. Methods: A qualitative content analysis research was done. The present study investigated patients' experience and behaviors after hearing about their cancer. Purposeful sampling was carried out and continued until data saturation. We used qualitative validation methods to verify the results. Results: Study participants consisted of 14 patients. 10 main components emerged from the data including: 1) getting shocked, 2) fear, 3) anxiety and stress, 4) guilt, 5) hopelessness, 6) depression, 7) isolation, 8) lack of affection and dependency on family members, 9) getting prepared to die and, 10) reviving spiritual relationship with God. Conclusions: There is a necessity to understand the mental feelings of cancer patients, and program suitable clinical interventions based on patients' mental needs. As the number of cancer patients is increasing, the results of the present study can be useful for patients' families and clinical personnel especially physicians and nurses in dealing with cancer patients.

show abstract

“…12,22 However, corresponding to previous repeatedly replicated findings, we did not found a significant association between FCR and cancer diagnosis. 3,4,[22][23][24][25] A further aim of this study was to identify high-risk baseline predictors for FCR before and after allogeneic PBSC transplantation. We examined the cumulative effects of baseline clinical risk factors on FCR.…”

Section: Discussionmentioning

confidence: 99%

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Sarkar

Scherwath

Schirmer

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

We examined the course and the prevalence of a high fear of cancer recurrence (FCR) in patients undergoing allogeneic PBSC transplantation (hematopoietic SCT (HSCT)) before HSCT (N = 239), 100 days after (n = 150, and 12 months after allogeneic HSCT (n = 102). The Fear of Progression Questionnaire-Short Form (FoP-Q-SF), the EORTC Quality of Life Questionnaire, and the Hospital Anxiety and Depression Scale were used. Pre-HSCT 36% of patients, 100 days after HSCT 24% of patients, and 1 year after HSCT 23% of patients fulfilled the criteria for high FCR (FoP-Q-SF cutoff = 34). Being married (b = 2.76, P = 0.026), female gender (b = 4.45, Po 0.001) and depression (b = 4.44, P o 0.001) were significantly associated with FCR at baseline. One hundred days after HSCT, depression significantly predicted FCR (b = 6.46, Po 0.001). One year following HSCT, female gender (b = 6.61, P = 0.008) and higher depression were (b = 4.88, P = 0.004) significant predictors for FCR. Over the three assessment points, patients with high FCR had a significantly lower quality of life compared to patients with low FCR in physical functioning (P = 0.019), role functioning (P = 0.003), emotional functioning (P o 0.001), cognitive functioning (P = 0.003), social functioning (P o 0.001) and global quality of life (P o 0.001). Our data provide evidence that FCR is a prevalent problem in patients with hematological malignancies and has a significant adverse impact on health-related quality of life.

show abstract

Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study

Cited by 153 publications

References 55 publications

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Investigating the Mental Experience of Patients Suffering From Cancer

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Contact Info

Product

Resources

About